Jiayuan Qu 1 , Mohammad Amjad Kamal 2,3 , Chengfu Yuan 1 Show Affiliations »
Abstract
BACKGROUND: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs. METHODS: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database. RESULTS/CONCLUSION: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
BACKGROUND: Ovarian cancer is the most malignant tumor in gynecological tumors , with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs. METHODS: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer , drug resistance, and LncRNA retrieved from the LncRNA Disease database. RESULTS/CONCLUSION: With the development of the study on drug resistance of ovarian cancer , the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Entities: Disease
Keywords:
LncRNA; Ovarian cancer; chemoresistance; drug resistance; gynecological tumors; long non-coding RNA.
Mesh： See more »
Substances： See more »
Year: 2019
PMID： 30947657 DOI： 10.2174/1381612825666190404122154
Source DB: PubMed Journal: Curr Pharm Des ISSN： 1381-6128 Impact factor: 3.116